Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY2253651 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A single dose BAY2253651 | EXPERIMENTAL | Single dose BAY2253651 |
| Part A single dose Placebo | PLACEBO_COMPARATOR | Single dose matching placebo |
| Part B multiple dose BAY2253651 | EXPERIMENTAL | Multiple dose BAY2253651 on 5 consecutive nights |
| Name | Type | Description |
|---|---|---|
| BAY2253651 | DRUG | 100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally |
| Placebo | DRUG | Matching Placebo dosing |
Inclusion Criteria: * Subjects need to be diagnosed with OSA (obstructive sleep apnea) but should be otherwise healthy at the discretion of the investigator. * Patients must be pretreated with CPAP (continuous positive airway pressure) for OSA for at least 3 months before randomization. * AHI of 15...
BAY2253651 is an investigational small molecule being studied for the treatment of Obstructive Sleep Apnea (OSA). It is a potassium channel inhibitor that was evaluated in a Phase 2 clinical trial. The drug is being developed by Bayer AG and is not yet approved for any use.
BAY2253651 targets potassium channels, acting as a potassium channel inhibitor. This mechanism was studied in the context of treating Obstructive Sleep Apnea. The drug is a small molecule developed by Bayer AG and is currently in clinical development.
BAY2253651 is being developed by Bayer AG, a multinational pharmaceutical company. The company's stock is traded under the ticker BAYRY. The drug is an investigational small molecule being studied for Obstructive Sleep Apnea and is currently in Phase 2 clinical development.
BAY2253651 is in Phase 2 clinical development. It has completed one Phase 2 trial for Obstructive Sleep Apnea. The drug is investigational and has not been approved by regulatory authorities. It is being developed by Bayer AG.
BAY2253651 has been studied in one completed Phase 2 clinical trial, identified as NCT03603678. The trial was titled "Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor" and enrolled 34 participants in Switzerland and the United Kingdom. The study was randomized, double-blind, and placebo-controlled.
BAY2253651 is the same drug as BAY 2253651, with the name typically written without spaces. It is an investigational small molecule being developed by Bayer AG for Obstructive Sleep Apnea. The drug has completed a Phase 2 clinical trial and is not yet approved.